The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rodin Therapeutics today announced the initiation of a Phase 1 clinical trial of the company’s lead candidate, RDN-929, a potent and selective HDAC-CoREST inhibitor.
IMpactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results